Abstract
The clinical manifestations of AIDS (acquired immune deficiency syndrome) often include neuropsychiatric and neurological deficits1–4, including early memory loss and progressive dementia. HIV (human immunodeficiency virus), the aetiological agent of AIDS, is probably carried by infected macrophages in the central nervous system5–7. The virus enters cells by binding its envelope glycoprotein gp120 to the CD4 antigen8–10 present on brain and immune cells11–13. From the data reported in this paper, we now suggest that the neuronal deficits associated with HIV may not be entirely a result of infectivity, but that gp120 shed from HIV14–16 could directly produce the neuropathology as a result of its interference with endogenous neurotrophic substances. It is known that an analogue of a sequence contained in vasoactive intestinal peptide (VIP) occurs in all known sequenced gp120 isolates17–20 and that VIP is important for neuronal survival in cell culture21–23. Here we show that purified gp120 from two diverse HIV isolates and a recombinant gp120 from a third isolate were all potent in specifically producing significant neuronal cell death in dissociated hippocampal cultures derived from fetal mice, and that this could be reduced by monoclonal antibodies against the murine24 CD4 antigen and completely antagonized by VIP.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Snider, W. D. et al. Ann. Neurol. 14, 403–418 (1983).
Ultmann, M. H. et al. Devl Med. & Child Neurol. 27, 563–571 (1985).
Navia, B. A. & Price, R. W. Archs Neurol. 44, 65–69 (1987).
Lowenstein, R. J. & Sharfstein, S. S. Int. J. Psychiatry Med. 13, 255–260 (1983–84).
Gartner, S. et al. Science 233, 215–219 (1986).
Koenig, S. et al. Science 233, 1089–1093 (1986).
Price, R. W., Navia, B. A. & Cho, E. Neurol. Clinics 4, 285–301 (1986).
Dalgleish, A. G. et al. Nature 312, 763–767 (1985).
McDougal, J. S. et al. J. Immun. 135, 3151–3162 (1984).
Klatzmann, D. et al. Nature 312, 767–768 (1984).
Perry, V. H. & Gordon, S. J. exp. Med. 166, 1138–1143 (1987).
Pert, C. B. et al. Proc. natn. Acad. Sci. U.S.A. 83, 9254–9258 (1986).
Hill, J. M., Farrar, W. L. & Pert, C. B. Psychopharmaco. Bull. 22, 689–694 (1986).
Gelderblom, H. R., Hausmann, E. H. S., Ozel, M., Pauli, G. & Koch, M. A. Virology 156, 171–176 (1987).
Pahwa, S. Pahwa, R., Saxinger, C., Gallo, R. C. & Good, R. A. Proc. natn. Acad. Sci. U.S.A. 82, 8198–8202 (1985).
Schneider, J., Kaaden, O., Copeland, T., Oroszlan, S. & Hunsmann, G. J. gen. Virol. 67, 2533–2438 (1986).
Ruff, M. R., Martin, B. M., Ginns, E. I., Farrar, W. L. & Pert, C. B. FEBS Lett. 211, 17–22 (1987).
Sacerdote, P., Ruff, M. R. & Pert, C. B. J. Neurosci. Res. 18, 102–107 (1987).
Pert, C. B. & Ruff, M. Clin. Neuropharm. 9, 482–484 (1986).
Ruff, M. R. et al. Lancet 8561, 751 (1987).
Brenneman, D. E. & Eiden, L. E. Proc. natn. Acad. Sci. U.S.A. 83, 1159–1162 (1986).
Brenneman, D. E., Eiden, L. E. & Siegel, R. E. Peptides 6, Suppl. 2, 35–39 (1985).
Brenneman, D. E., Neale, E. A., Foster, G. A., d'Autremont, S. W. & Westbrook, G. L. J. cell. Biol. 104, 1603–1610 (1987).
Tourvieille, B., Gorman, S. D., Field, E. H., Hunkapiller, T. & Parnes, J. R. Science 234, 610–614 (1986).
Dialynas, D. P. et al. J. Immun. 131, 2445–2451 (1983).
Swain, S. L., Dialynas, D. P., Fitch, F. W. & English, M. J. Immun. 132, 1118–1123 (1984).
Ceredig, R., Lowenthal, J. W., Nabholz, M. & MacDonald, H. R. Nature 314, 98–100 (1985).
Kincade, P. W., Lee G., Sun, L. & Watanabe, T. J. Immun. Meth. 42, 17–26 (1981).
Eisenbarth, G. S., Walsh, F. S. & Nirenberg, M. Proc. natn. Acad. Sci. U.S.A. 76, 4913–4917 (1979).
Rostene, W. H. Prog. Neurobiol. 22, 103–129 (1984).
O'Dorisio, M. S., Wood, C. L., Wenger, G. D. & Vassalo, L. M. J. Immun. 134, 4078–4086 (1985).
Pert, C. B. et al. Ann. Neurol. 23, S71–S73 (1988).
Gurney, M. E., Heinrich, S. P., Lee, M. R. & Yin, H. Science 234, 566–574 (1986).
Weigent, D. A. et al. Biochem. biophys. Res. Commun. 139, 367–374 (1986).
Kleinerman, E. S., Lachman, L. B., Knowles, R. D., Snyderman, R. & Cianciolo, G. J. J. Immun. 139, 2329–2337 (1987).
Brenneman, D. E., Buzy, J. M., Ruff, M. R. & Pert, C. B. Drug Dev. Res. (in the press).
Sharer, L. R. et al. Hum. Path. 17, 271–284 (1986).
Robey, W. G. et al. Proc. natn. Acad. Sci. U.S.A. 83, 7023–7027 (1986).
Rusche, J. R. et al. Proc. natn. Acad. Sci. U.S.A. 84, 6924–6928 (1987).
Forsythe, I. D. & Westbrook, G. L. J. Physiol., Lond. 396, 515–533 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brenneman, D., Westbrook, G., Fitzgerald, S. et al. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335, 639–642 (1988). https://doi.org/10.1038/335639a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/335639a0
This article is cited by
-
Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury
Journal of Neuroimmune Pharmacology (2021)
-
NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology
Cellular & Molecular Immunology (2020)
-
CXCR4 and NMDA Receptors Are Functionally Coupled in Rat Hippocampal Noradrenergic and Glutamatergic Nerve Endings
Journal of Neuroimmune Pharmacology (2016)
-
Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV
Journal of NeuroVirology (2015)
-
PACAP27 is Protective Against Tat-Induced Neurotoxicity
Journal of Molecular Neuroscience (2014)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.